Equillium Inc (EQ)

[trustbutverifyit]

Equillium Shares Up 16% After Getting FDA Fast-Track Designation

12/10/19, 1:37 PM
Equillium Inc. (EQ) shares rose 16% to $4.68 after the company said the U.S. Food and Drug Administration has granted fast-track designation for itolizumab for the treatment of lupus nephritis.

Equillium said it initiated the Equalise Phase 1b study of itolizumab in patients with lupus and lupus nephritis in September.

The biotechnology company said the trial will be assessing the opportunity to take a personalized medicine approach to identify patients where the CD6-ALCAM pathway may be a dominant driver of the disease. There are currently no FDA- approved therapies for lupus nephritis, Equillium said.